Yang Chinglai, Ye Ling, Compans Richard W
Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA.
Expert Rev Vaccines. 2008 Apr;7(3):333-44. doi: 10.1586/14760584.7.3.333.
Significant progress has been made in vaccine development against infection by Ebola and Marburg viruses, members of the Filoviridae, which cause severe hemorrhagic fevers in humans with no effective treatment and a mortality rate of up to 90%. Several vaccine strategies have been shown to effectively protect immunized animals against filovirus infection. Among these candidate vaccine strategies, virus-like particles represent a promising approach and have been shown to protect small laboratory animals as well as nonhuman primates against lethal challenge by Ebola and/or Marburg viruses. This review briefly summarizes filovirus epidemiology and pathogenesis, and focuses on the discussion of recent advances in filovirus vaccine development and the current understanding of protective immune responses against filovirus infection with an emphasis on the progress and challenge of filovirus virus-like particle vaccine development.
在针对丝状病毒科成员埃博拉病毒和马尔堡病毒感染的疫苗研发方面已取得重大进展，这些病毒会导致人类严重出血热，且没有有效的治疗方法，死亡率高达90%。几种疫苗策略已被证明能有效保护免疫动物免受丝状病毒感染。在这些候选疫苗策略中，病毒样颗粒是一种有前景的方法，已被证明能保护小型实验动物以及非人灵长类动物免受埃博拉病毒和/或马尔堡病毒的致死性攻击。本文综述简要总结了丝状病毒的流行病学和发病机制，并着重讨论丝状病毒疫苗研发的最新进展以及目前对丝状病毒感染保护性免疫反应的认识，重点是丝状病毒病毒样颗粒疫苗研发的进展和挑战。
